Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gossamer Bio Inc.

1.36
0.0000
Post-market: 1.370.0100+0.74%19:30 EDT
Volume:696.09K
Turnover:956.93K
Market Cap:309.13M
PE:-6.01
High:1.40
Open:1.34
Low:1.34
Close:1.36
Loading ...

Gossamer Bio Inc. Conducted Annual Stockholders Meeting

Reuters
·
26 Jun

Gossamer Bio Completes Enrollment in Phase 3 PROSERA Study for PAH Treatment, Topline Results Expected February 2026

Reuters
·
16 Jun

Gossamer Bio Inc. Enters Global Collaboration Agreement with Chiesi Group for Development of Seralutinib

Reuters
·
16 Jun

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 Prosera Study for the Treatment of Pah

THOMSON REUTERS
·
16 Jun

Gossamer Bio Inc - Topline Results From Phase 3 Prosera Study Expected February 2026

THOMSON REUTERS
·
16 Jun

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule

Reuters
·
07 Jun

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jun

Gossamer Bio Is Maintained at Buy by Goldman Sachs

Dow Jones
·
17 May

Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush

Dow Jones
·
16 May

Piper Sandler Remains a Buy on Gossamer Bio (GOSS)

TIPRANKS
·
16 May

Gossamer Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate

Benzinga
·
16 May

BRIEF-Gossamer Bio Q1 EPS USD -0.16

Reuters
·
16 May

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 Prosera Study

THOMSON REUTERS
·
16 May

Gossamer Bio Q1 Operating Expenses USD 46.699 Million

THOMSON REUTERS
·
16 May

Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
13 May

Press Release: Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Dow Jones
·
13 May

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 May

Gossamer Bio Inc. to Present Preclinical Data on Seralutinib at American Thoracic Society International Conference

Reuters
·
08 May

Gossamer Bio Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
02 May